Tiziana Life Sciences – Exercise of Warrants & Issue of Equity & Total Voting Rights July 24, 2020 – Posted in: Uncategorized

24th July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 24 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 88,580 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of…

Tiziana Life Sciences – Agreement with STC Biologics June 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 29th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Agreement with STC Biologics Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19. · This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19 New York/London – 29…

Tiziana Life Sciences plc – Exercise of Warrants and Issue of Equity and Total Voting Rights June 22, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 22nd June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 22 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 1,800,000 ordinary shares of 3 pence each (“New Ordinary Shares”)…

Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases June 19, 2020 – Posted in: Tiziana Life Sciences (TILS)

Friday 19th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases · First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies · Transformational oral formulation technologies applicable to other antibodies This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 19 June 2020…

Tiziana Life Sciences – Final Results June 18, 2020 – Posted in: Tiziana Life Sciences (TILS), Uncategorized

Thursday 18th June, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Final Results for the Year Ended 31 December 2019 London / New York 18 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces its financial results for the year ended 31 December 2019. This announcement contains inside…

Tiziana Life Sciences – Dr. Howard Weiner has received a competitive research grant from the National Institute of Health (NIH) June 4, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 4 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious…

Tiziana Life Sciences Plc – Exercise of Warrants and Issue of Equity and Total Voting Rights June 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Correction – Exercise of Warrants and Issue of Equity and Total Voting Rights The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding £710,843 in cash proceeds, the announcement should have stated the number of shares to be issued is 1,234,399, yielding £578,700 cash proceeds. All other details in the announcement remain unchanged. The amended announcement is set out below:…

Tiziana Life Sciences – TR1 Notification – Quilter Plc May 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an…

Tiziana Life Sciences (TILS) Interim Results for the Six Months Ended 30 June 2019 September 30, 2019 – Posted in: Tiziana Life Sciences (TILS)

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 30 September 2019 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended 30 June 2019. Highlights during the period: RESEARCH & DEVELOPMENT CLINICAL PROGRAMMES Foralumab TZLS-401 Foralumab…